JAK inhibitor
A class of targeted synthetic DMARDs that block Janus kinase signaling pathways involved in inflammatory cytokine responses.
Full Definition
JAK inhibitors are oral small-molecule drugs that selectively inhibit one or more Janus kinase enzymes (JAK1, JAK2, JAK3, TYK2), which are crucial components of cytokine signaling pathways. In pediatric rheumatology, these medications represent an emerging therapeutic option for juvenile idiopathic arthritis and other inflammatory conditions. Tofacitinib was the first JAK inhibitor approved for polyarticular course JIA in children. These drugs offer advantages including oral administration and rapid onset of action, but require monitoring for potential side effects including infection risk, laboratory abnormalities, and growth in pediatric patients.
Usage
Usage note: Emerging class in pediatric rheumatology; emphasize oral administration advantage.
In Context
- "The adolescent showed excellent response to JAK inhibitor therapy when biologics were contraindicated." — Treatment algorithm note
- "JAK inhibitor monitoring protocols include regular assessment of lymphocyte counts and liver function." — Safety monitoring guideline